Sydney, Jan 28, 2026, 07:02 AEDT — Premarket
- Telix Pharmaceuticals (ASX:TLX) closed Tuesday 8.3% higher, at A$11.86.
- A fresh “substantial holder” notice revealed JPMorgan Chase & Co. holds 5.54% voting power.
- Short interest is still elevated, fueling bigger daily moves.
Telix Pharmaceuticals Ltd shares grabbed attention ahead of the Australian open, closing Tuesday up 8.31% at A$11.86. The jump came after the company filed a fresh “substantial holder” notice with the exchange. Intelligent Investor
Telix’s rebound catches attention, given it’s been one of healthcare’s worst performers in the last year, plunging roughly 57% over 12 months, according to market data. The company focuses on therapeutic and diagnostic radiopharmaceuticals — radioactive drugs for imaging and treatment — with Illuccix as its flagship imaging product.
Telix is also a popular target for short sellers, with 11.27% of its shares shorted, according to a Market Index compilation. That places it among the ASX’s most heavily shorted stocks. Since short selling bets on a stock’s decline, intense short interest can accelerate price moves when things start shifting.
A Form 603 filing revealed that JPMorgan Chase & Co. and its affiliates now control 5.54% of voting rights in Telix, equating to roughly 18.75 million ordinary shares, after first becoming a substantial holder on Jan. 21. The report detailed a range of positions, including securities lending and prime brokerage-related holdings—reflecting the complex interplay of borrowed and loaned stock—rather than straightforward stock purchases.
Telix’s shares fluctuated from A$10.91 to A$11.94 on Tuesday, with roughly 3.65 million shares changing hands, per exchange data reported by .
Local stocks gained ground, with the ASX 200 up 0.9% on Tuesday. Materials, tech, and healthcare sectors led the charge, while Telix stood out as a top performer, according to an ABC Markets summary.
Telix’s Nasdaq-listed shares climbed roughly 8.9% to $8.33 in the most recent session, according to market data. The stock opened at $8.10 and hit a peak of $8.34 during trading.
Still, that disclosure comes with a clear warning for traders hunting a straightforward signal. Crossing the 5% threshold might indicate client facilitation, stock lending, or hedged exposure—moves that can reverse fast and don’t necessarily signal bullishness.
On Wednesday, investors will be keen to see if Tuesday’s surge sparks more buying or loses steam quickly, and if additional shareholder disclosures or changes in short positions emerge in the wake of the rally.
Telix’s next major date is its earnings report, scheduled for around Feb. 19, per Nasdaq’s earnings calendar.
